SAKK – YOUNG ONCOLOGY ACADEMY - Was junge Onkologen von ESMO - EHA - ESTRO und ESP berichten — EHA 2024 Congress
Advances in cellular therapies
In this article we review 2 studies on CD19 CAR-T cells, which were presented at the annual meeting of the European Hematology Association (EHA) 2024 in Madrid, Spain. The first study investigates the efficacy and safety of CD19 CAR-T cell therapies in ≥75 years old patients. The second trial explores if CD19 CAR-T cells expressing interleukin-10 (IL-10) are more resilient to exhaustion and ultimately show a better response rate in DLBCL or B-ALL.